Market Overview

Wells Fargo Says Outside Interest in Multiple Myeloma Space a Positive for Array Biopharma

Related ARRY
Events Scheduled for Week of Jun. 16th to Jun. 20th
Array BioPharma Collaborates with Biogen - Analyst Blog
Related AMGN
Morgan Stanley Issues 2015 'Vintage Values' Stock List
Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector
Drug Giants Advance Cancer Treatments (Fox Business)

Array Biopharma (NASDAQ: ARRY) shares are up over 5 percent in Monday's afternoon session as the earlier Amgen (NASDAQ: AMGN), Onyx (NASDAQ: ONXX) bid and the Celgene (NASDAQ: CELG) MorphoSys partnership signals significant interest in the multiple myeloma space, according to Wells Fargo's Matthew Andrews.

The analyst believes Array's ARRY-520 is an under-appreciated asset in this field.

Andrews maintains an Outperform rating on shares of Array Biopharma.

Posted-In: Analyst Color Analyst Ratings

 

Most Popular

Related Articles (AMGN + ARRY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free